Skip to main
MAZE

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics Inc is exhibiting a positive outlook due to its innovative approach to developing precision medicines for chronic kidney disease through its Compass platform, which utilizes variant functionalization to link genetic variants to disease pathways. The promising efficacy signals observed in the Phase 2 HORIZON trial for MZE829, combined with the favorable data from MZE782's Phase 1 trials, enhance the likelihood of achieving accelerated approval from regulators, potentially positioning the company for significant market entry advantages. Furthermore, the anticipated peak penetration increase of MZE829 in the treatment landscape demonstrates strong confidence in the company’s growth potential, bolstering its overall market appeal.

Bears say

Maze Therapeutics Inc faces significant risks regarding its investigational drug, inaxaplin, particularly pertaining to inflated efficacy signals that may result from treatment outcomes in diverse patient cohorts. The variability in patient response, such as a notable portion (25%) experiencing inadequate response to SGLT2 inhibitor therapies, raises concerns about the reliability of the company's therapeutic approaches in chronic kidney disease contexts. Moreover, the observed eGFR declines in patients suggest that without stabilization through adequate treatment regimens, the company's pipeline may experience severe setbacks, potentially leading to a 30% downside risk in stock performance.

MAZE has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 8 analysts, MAZE has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.